Available Until 10/5/2024

The Evolving Role of Sodium-glucose Co-transporter 2 (SGLT2) inhibitors in Patients without Type 2 Diabetes

Planned in cooperation with the ASHP Section of Inpatient Care Practitioners

ACPE Activity Number: 0204-0000-21-080-H01-P
Release Date: October 5, 2021
Expiration Date: October 5, 2024
Activity Type: Knowledge-based  
CE Credits: 1.0 contact hour, (0.10 CEUs) no partial credit
Activity Fee: Members – Free / Non-Member – Not Available

This activity is a recording from a live webinar and those that claim credit for the live webinar should not claim credit for this activity.

Activity Overview

Sodium-glucose Co-transporter 2 (SGLT2) inhibitors have gained favor in the management for diabetes due to added benefit in patients with co-morbid cardiovascular and kidney disease. Emerging data indicate that this class of medications may be useful in patients without diabetes. This webinar will discuss available literature evaluating the use of SGLT2 inhibitors in non-diabetic patients with heart failure with reduced ejection fraction (HFrEF) and/or chronic kidney disease (CKD). Also, guidance will be provided on how to effectively implement these agents into formulary considerations and improve access in patient care.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity was planned to meet the educational needs of ASHP pharmacist members in both the acute and ambulatory care settings.

  1. Describe the role of SGLT2 inhibitors in management of heart failure with reduced ejection fraction (HFrEF) as a guideline-directed medical therapy.
  2. Discuss how to incorporate SGLT2 inhibitors into the overall management of chronic kidney disease (CKD).
  3. Identify formulary considerations related to Sodium-glucose Co-transporter 2 (SGLT2) inhibitors that can improve access to these medications for patients with HFrEF and CKD.

  • Introduction and Announcements
  • Presentation
  • Questions, Answers, and Discussion

  • Sandeep Devabhakthuni, Pharm.D., BCCP, Associate Professor, Cardiology, Director of Postgraduate Training, University of Maryland School of Pharmacy, Baltimore, MD
  • Indrani Kar, Pharm.D., Drug Policy/Formulary Specialist, System Pharmacy Services, University Hospitals, Cleveland, Ohio
  • Moderator and Speaker: C. Whitney White, Pharm.D., BCPS, Clinical Pharmacy Specialist. Tuscaloosa VA Medical Center, Tuscaloosa, AL

In accordance with the ACPE's and ACCME's Standards for Commercial Support, anyone in a position to control the content of an educational activity is required to disclose to the accredited provider their relevant financial relationships. In accordance with these Standards, all potential conflicts of interest have been resolved. An individual has a relevant financial relationship if he or she (or spouse/domestic partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the activity content over which the individual has control.

As defined by ACCME, a commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The Standards for Commercial Support do not consider providers of clinical service directly to patients to be commercial interests. The existence or non-existence of relevant financial relationships will be disclosed to the activity audience. All identified conflicts of interest must be resolved prior to the activity.

  • All planners, presenters, reviewers, and ASHP staff report no financial relationships relevant to this activity.

This activity consists of a recordings of faculty slides presentations, active learning activities, discussion, and handouts. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP eLearning Portal. Follow the prompts online to complete the evaluation, claim credit and view the statement of credit immediately after completing the activity.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Claim your CE at http://elearning.ashp.org. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.